Drug Profile
BAT 1306
Alternative Names: BAT1306Latest Information Update: 06 Jan 2023
Price :
$50
*
At a glance
- Originator Bio-Thera Solutions
- Developer Bio-Thera Solutions; Sun Yat-Sen University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- No development reported Colorectal cancer
Most Recent Events
- 06 Jan 2023 No development reported - Phase-II for Colorectal cancer (Combination therapy) in China (Parenteral)
- 31 Dec 2019 Bio-Thera completes a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, second-line therapy or greater) in China (ChiCTR1900027506)
- 15 Apr 2019 BioThera plans a phase II trial for Gastric cancer (First-line therapy, Late-stage disease) in China (ChiCTR1900022184)